Lurbinectedin Active in BRCA Mutation-positive Metastatic Breast Cancer

Share this content:
Lurbinectedin induces DNA double-strand breaks, and  regulates the tumor microenvironment.
Lurbinectedin induces DNA double-strand breaks, and regulates the tumor microenvironment.

Lurbinectedin, a novel investigational drug that inhibits trans-activated transcription, induces DNA double-strand breaks, and  regulates the tumor microenvironment, displays anti-tumor activity in patients with BRCA1/2-associated metastatic breast cancer, according to a study presented at the European Society for Medical Oncology (ESMO) 2016 Congress.1

Previous studies demonstrate activity with lurbinectedin in various tumor types, as well as in patients resistant to platinum-based chemotherapy. Researchers therefore assessed the activity of lurbinectedin among patients with metastatic breast cancer and deleterious germline BRCA mutations.

For the phase 2 clinical trial (ClinicalTrials.gov Identifier: NCT01525589), researchers enrolled 54 patients who received no more than 3 prior lines of chemotherapy for advanced or metastatic disease. Of those, 30 were BRCA1 mutation-positive and 31 had triple-negative disease.

Most had received prior treatment with anthracyclines and taxanes; half had received platinum agents and 9 were previously treated with PARP inhibitors.

The objective response rate was 39% (95% CI, 26-54), with 2% of the 51 evaluable patients achieving a complete response and 37% having partial responses. Among platinum pretreated patients, 23% (95% CI, 9-44) achieved an objective response.

Median duration of response was 4.6 months (95% CI, 3.4-11.3); median progression-free survival was 4.1 months (95% CI, 2.6-6.0).

RELATED: Q&A: With Dr Anna Boltong: The Link Between Alcohol and Breast Cancer

The most frequently reported grade 3 to 4 treatment-related adverse events were neutropenia, febrile neutropenia, thrombocytopenia, fatigue, transaminase elevation, and nausea.

The findings suggest that further evaluation of lurbinectedin in a phase 3 clinical trial is warranted.                

Reference

  1. Balmana J, Cruz C, Arun BK, et al. Anti-tumor activity of PM01183 (lurbinectedin) in BRCA1/2-associated metastatic breast cancer patients: results of a single-agent phase II trial. Paper presented at: European Society for Medical Oncology (ESMO) 2016 Congress; October 7-11, 2016; Copenhagen, Denmark.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs